About this trial
In pulmonary arterial hypertension (PAH), progressive pulmonary vascular remodeling leads to supraphysiologic right ventricular (RV) afterload. Pharmacologic trials have shown that aggressive upfront treatment reversing pulmonary vascular remodeling successfully increases RV function and improves survival. To date, however, there are no proven treatments that target RV contractile function.
Echocardiographic studies of RV dysfunction in the setting of pressure overload have demonstrated intra and interventricular dyssynchrony even in the absence of overt right bundle branch block (RBBB).
Electrophysiologic studies of patients with chronic thromboembolic disease (CTEPH) at the time of pulmonary endarterectomy have shown prolongation of action potential and slowed conduction in the right ventricle which has correlated with echocardiographic measures of dyssynchrony.
Cardiac MRI measures of RV strain in patients with PAH demonstrated simultaneous initiation of RV and left ventricular (LV) contraction, but delayed peak RV strain suggesting that interventricular dyssynchrony is a mechanical rather than electrical phenomenon.
Prior studies of RV dysfunction in an animal model, computer model, congenital heart disease, and CTEPH have suggested acute hemodynamic benefits of RV pacing. However, RV pacing has not been studied in patients with PAH. Furthermore, it remains unclear if pacing particular regions of the RV can achieve a hemodynamic benefit and what cost this hemodynamic improvement may incur with regards to myocardial energetics and wall stress.
Therefore, the investigators propose to examine RV electrical activation in PAH, map the area of latest activation, and then evaluate the hemodynamic and energetic effects of RV pacing in these patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients referred for a clinically indicated right heart catheterization to either diagnose pulmonary arterial hypertension prior to initiating therapies or monitor response to ongoing therapies in patients with diagnosed pulmonary arterial hypertension.
Patients with pulmonary arterial hypertension with or without significant right ventricular dysfunction as assessed by baseline echocardiography and standard of care right heart catheterization
Functional class 2 or 3 symptoms
Are able to undergo cardiac MRI, endocardial mapping, and pressure volume measurements
Disqualifiers
Preexisting left bundle branch block, current atrial fibrillation, or pacemaker/ defibrillators
Functional class 4 symptoms
Patients treated with parenteral or subcutaneous therapies for pulmonary hypertension
Contraindication to right heart catheterization including significant thrombocytopenia (platelets < 50,000), coagulopathy (INR > 1.8), or pregnancy as determined by routine screening laboratory work
Trial design
Single group
Treatments tested in this trial
Temporary right ventricular pacing
Procedure/SurgeryAs described previously. Patients will undergo temporary pacing at the site of latest endocardial activation with measurement of hemodynamic effects.
Treatment groups
Trial outcomes
Primary outcomes
Change in contractility (Ees)
This is an invasive measure of the contractile strength of the right ventricle that is measured using pressure volume measurements from within the ventricle itself.
Secondary outcomes
Change in stroke volume
This is an invasive measure of the amount of blood ejected by the heart with each heart beat.
Pressure-volume loop area
The pressure-volume loop area will be calculated to assess right ventricular myocardial oxygen consumption
Coronary sinus oxygen saturation
Global myocardial oxygen consumption will also be assessed via measurement of the coronary sinus oxygen saturation.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.